Skip to content
DataLookout
Menu

NCT06379646

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Apr 21, 2027 Show 6 more changesShow less
    • Start date pushed from Apr 24, 2024 to Oct 24, 2024
    • Eligibility criteria expanded, about 49 words
    • Primary endpoints: details revised at 1 of 7 entries
    • Trial status changed: Unknown → Recruiting
    • Secondary endpoints: details revised at 6 of 10 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary endpoints revised (7)
    • Trial status: Recruiting to Unknown
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 22, 2024 to Apr 24, 2024
    • Secondary endpoints: 4 to 10
    • Study description shortened, about 17 words
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: 3 months for safety measurements during the treatment assessment period
Efficacy outcomes for SLE
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Sjogren's Syndrome
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Systemic Sclerosis
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Inflammatory Myopathy
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Antiphospholipid Syndrome
Timeframe: 3 months for efficacy measurements during the treatment assessment period

Secondary (10)

Peak Plasma Concentration (Cmax) of YTS109
Time to Peak (Tmax) of YTS109
Area under the plasma concentration versus time curve (AUC) of YTS109
PD parameters
Efficacy outcomes for SLE
Show 5 moreShow less
Efficacy outcomes for Sjogren's Syndrome
Efficacy outcomes for Systemic Sclerosis
Efficacy outcomes for Inflammatory Myopathy
Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Efficacy outcomes for Antiphospholipid Syndrome

Arms and interventions

YTS109Experimental

YTS109 cell injection

Other: YTS109

Sites

1 site in 1 country

  • Shanghai Changzheng HospitalShanghai, Shanghai Municipality, China